In the context of previously published preclinical work demonstrating that blocking IL-1 signaling can inhibit osteosarcoma metastasis, our work supports the development of a clinical trial testing this concept in patients with osteosarcoma. The gene discussed is IL1B; the disease is osteosarcoma.